ArticleTranslational research : the journal of laboratory and clinical medicine2007
Role of the angiotensin II type-2 receptor in radiation nephropathy.
Article in Translational research : the journal of laboratory and clinical medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- Radiation Induced Skin Fibrosis (RISF): Opportunity for Angiotensin II-Dependent Intervention.International journal of molecular sciences · 2024Review
- Radiation-induced kidney toxicity: molecular and cellular pathogenesis.Radiation oncology (London, England) · 2021Review
- Cardiac injury after 10 gy total body irradiation: indirect role of effects on abdominal organs.Radiation research · 2013Article
- Evaluation of Genomic Evidence for Oxidative Stress in Experimental Radiation Nephropathy.Journal of genetic disorders & genetic reports · 2013Article
- Dietary selenium for the mitigation of radiation injury: effects of selenium dose escalation and timing of supplementation.Radiation research · 2011Article
- Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation.Radiation research · 2011Article
- Mitigation of radiation injuries via suppression of the renin-angiotensin system: emphasis on radiation nephropathy.Current drug targets · 2010Review
- Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?Current drug targets · 2010Review
- The urine proteome for radiation biodosimetry: effect of total body vs. local kidney irradiation.Health physics · 2010Article
- 10 Gy total body irradiation increases risk of coronary sclerosis, degeneration of heart structure and function in a rat model.International journal of radiation biology · 2009Article
- Radiation nephropathy is not mitigated by antagonists of oxidative stress.Radiation research · 2009Article
- High-dose selenium for the mitigation of radiation injury: a pilot study in a rat model.Radiation research · 2009Article
- Chronic oxidative stress as a mechanism for radiation nephropathy.Radiation research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Experimental studies have shown that blockade of the angiotensin II type-1 (AT(1)) receptor is effective in the mitigation and treatment of radiation-induced chronic renal failure. Also, blockade of the angiotensin II type-2 (AT(2)) receptor with PD-123319 also had a modest, but reproducible, beneficial effect in experimental radiation nephropathy, and it might augment the efficacy of an AT(1) blocker (L-158,809). Those studies could not exclude the possibility that the effects of AT(2) blockade were nonspecific. The current studies confirm the efficacy of AT(2) blockade for mitigation of experimental radiation nephropathy but paradoxically find no detectable level of AT(2) receptor binding in renal membranes. However, the results of a bioassay showed that the circulating levels of the AT(2) blocker were orders-of-magnitude too low to block AT(1) receptors. The effect of AT(2) blockade in radiation nephropathy cannot be explained by binding to the AT(1) receptor, and the efficacy of the AT(1) blockade in the same model cannot be explained by unopposed overstimulation of the AT(2) receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.